Is CRTX or DGRO a better dividend investment in 2026?

CRTX currently yields 102.56% with a 5% 5-year dividend growth rate. DGRO yields 2.13% with 9.5% growth. The better choice depends on your goal: CRTX offers higher current income.

What is the dividend yield difference between CRTX and DGRO?

CRTX has a forward dividend yield of 102.56% ($2.00/share annually). DGRO yields 2.13% ($1.47/share annually). The yield gap is 100.43 percentage points.

Home › Compare › CRTX vs DGRO

CRTX vs DGRO: Dividend Comparison 2026

CRTX yields 102.56% · DGRO yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CRTX wins by $4.29M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CRTX

● Live price

102.56%

Share price

$1.95

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.32M

Annual income

$1,481,817.76

Full CRTX calculator →

DGRO

iShares Core Dividend Growth ETF

● Live price

2.13%

Share price

$68.98

Annual div

$1.47

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.6K

Annual income

$239.96

Full DGRO calculator →

Portfolio growth — CRTX vs DGRO

📍 CRTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CRTX	DGRO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CRTX + DGRO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CRTX pays

DGRO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRTX

Annual income on $10K today (after 15% tax)

$8,717.95/yr

After 10yr DRIP, annual income (after tax)

$1,259,545.10/yr

DGRO

Annual income on $10K today (after 15% tax)

$181.24/yr

After 10yr DRIP, annual income (after tax)

$203.97/yr

At 15% tax rate, CRTX beats the other by $1,259,341.13/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRTX + DGRO for your $10,000?

CRTX: 50%DGRO: 50%

100% DGRO50/50100% CRTX

Portfolio after 10yr

$2.18M

Annual income

$741,028.86/yr

Blended yield

34.03%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRTX buys

DGRO buys

No recent congressional trades found for CRTX or DGRO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCRTXDGRO

Forward yield	102.56% ✓	2.13%
Annual dividend / share	$2.00 ✓	$1.47
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.32M	$31.6K ✓
Annual income after 10y	$1,481,817.76 ✓	$239.96
Total dividends collected	$3.87M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CRTX vs DGRO ($10,000, DRIP)

Year	CRTX Portfolio	CRTX Income/yr	DGRO Portfolio	DGRO Income/yr	Gap
1← crossover	$20,956	$10,256.41	$11,293	$213.22	+$9.7K → CRTX
2	$42,511	$20,087.62	$12,730	$217.32	+$29.8K → CRTX
3	$83,570	$38,082.81	$14,326	$221.10	+$69.2K → CRTX
4	$159,386	$69,966.82	$16,098	$224.56	+$143.3K → CRTX
5	$295,256	$124,712.82	$18,064	$227.74	+$277.2K → CRTX
6	$531,835	$215,911.30	$20,246	$230.65	+$511.6K → CRTX
7	$932,535	$363,471.12	$22,666	$233.30	+$909.9K → CRTX
8	$1,593,439	$595,626.55	$25,349	$235.73	+$1.57M → CRTX
9	$2,656,155	$951,175.34	$28,325	$237.94	+$2.63M → CRTX
10	$4,323,904	$1,481,817.76	$31,624	$239.96	+$4.29M → CRTX

CRTX vs DGRO: Complete Analysis 2026

CRTX — Stock

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Full CRTX Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →

📬

Get this CRTX vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRTX vs SCHD CRTX vs JEPI CRTX vs O CRTX vs KO CRTX vs MAIN CRTX vs VIG CRTX vs NOBL CRTX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.